José Miranda-Bautista1, Camilo Padilla-Suárez, Emilio Bouza, Patricia Muñoz, Luis Menchén, Ignacio Marín-Jiménez. 1. aDigestive Diseases Service bMicrobiology and Infectious Diseases Services, "Gregorio Marañón" General University Hospital, Health Investigation Institute "Gregorio Marañón" (IISGM) cOn-line Hepatic and Digestive Diseases Research Centre (CIBERehd), Carlos III Health Institute dDepartment of Medicine, "Complutense" University, Madrid, Spain.
Abstract
BACKGROUND: Listeria monocytogenes (LM) is a gram-positive intracellular bacillus that in immunodeficient patients, children, geriatric patients, pregnant women, and even in healthy individuals can cause central nervous system infection, bacteremia, and other clinical manifestations, becoming a relevant pathogen. MATERIALS AND METHODS: From the Microbiology Service data of 'Gregorio Marañón' Hospital, we selected all positive biological sample cultures for LM from inflammatory bowel disease (IBD) patients, from January 1986 until January 2011. These cases were included in an SPSS database, analyzing several basal clinical characteristics and factors related to the infection. RESULTS: Three patients diagnosed with IBD had positive cultures for LM during this period. All of them were male, and also all of them had a diagnosis of Crohn's disease. Every patient had a corticosteroid cumulated dose of more than 400 mg (equivalency in methylprednisolone doses), adding anti-tumor necrosis factor-α treatment (certolizumab) in one patient. Prior colonoscopy with biopsy was performed in two patients. Clinical presentation of the infection was bacteremia in two patients, accompanied by central nervous system infection in one patient. One patient had isolated meningoencephalitis. Despite correct empiric treatment, one patient died from a cause related to the infection, that is, rombencephalitis. Increased incidence of LM bacteremia was found in IBD patients, compared with the general population (12.2 bacteremias/100 000 IBD patient-years, compared with 1.6 bacteremias/100 000 person-years), with an odds ratio of 7.4. CONCLUSION: IBD patients may be at risk for more frequent and serious LM infection compared with the general population.
BACKGROUND:Listeria monocytogenes (LM) is a gram-positive intracellular bacillus that in immunodeficientpatients, children, geriatric patients, pregnant women, and even in healthy individuals can cause central nervous system infection, bacteremia, and other clinical manifestations, becoming a relevant pathogen. MATERIALS AND METHODS: From the Microbiology Service data of 'Gregorio Marañón' Hospital, we selected all positive biological sample cultures for LM from inflammatory bowel disease (IBD) patients, from January 1986 until January 2011. These cases were included in an SPSS database, analyzing several basal clinical characteristics and factors related to the infection. RESULTS: Three patients diagnosed with IBD had positive cultures for LM during this period. All of them were male, and also all of them had a diagnosis of Crohn's disease. Every patient had a corticosteroid cumulated dose of more than 400 mg (equivalency in methylprednisolone doses), adding anti-tumornecrosis factor-α treatment (certolizumab) in one patient. Prior colonoscopy with biopsy was performed in two patients. Clinical presentation of the infection was bacteremia in two patients, accompanied by central nervous system infection in one patient. One patient had isolated meningoencephalitis. Despite correct empiric treatment, one patient died from a cause related to the infection, that is, rombencephalitis. Increased incidence of LM bacteremia was found in IBDpatients, compared with the general population (12.2 bacteremias/100 000 IBDpatient-years, compared with 1.6 bacteremias/100 000 person-years), with an odds ratio of 7.4. CONCLUSION:IBDpatients may be at risk for more frequent and serious LMinfection compared with the general population.
Authors: Jordan E Axelrad; Ken H Cadwell; Jean-Frederic Colombel; Shailja C Shah Journal: Therap Adv Gastroenterol Date: 2021-03-31 Impact factor: 4.409
Authors: Olivier Disson; Camille Blériot; Jean-Marie Jacob; Nicolas Serafini; Sophie Dulauroy; Grégory Jouvion; Cindy Fevre; Grégoire Gessain; Pierre Thouvenot; Gérard Eberl; James P Di Santo; Lucie Peduto; Marc Lecuit Journal: J Exp Med Date: 2018-10-24 Impact factor: 14.307